Name | Nuvigil |
Synonyms | Nuvigil (R)-2-(benzhydrylsulfinyl)acetamide 2-[(R)-(Diphenylmethyl)sulfinyl]-acetamide |
CAS | 112111-43-0 |
Molecular Formula | C15H15NO2S |
Molar Mass | 273.354 |
Density | 1.283 |
Melting Point | 156-1580C |
Hazard Symbols | Xi - Irritant |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 - Wear eye / face protection. |
UN IDs | 41 |
CN200780006054.7
application date:
21 Feb 2007
Public/Announcement Number:
CN101454279
applicant (patent):
TWA Pharmaceutical Industry Co., Ltd.
inventor:
V · bloude ,R. Moshkwitz-karpstein ,S · Levay
National and provincial code:
Israel
cited:
Abstract:
The present invention includes a crystalline form of amodafenib, a method for preparing the crystalline form, and a pharmaceutical formulation.
sovereignty:
1. A crystalline form of armodafinil characterized by a powder XRD pattern at approximately 6.5, 10.3, 17.9, 19.5 and 21.8±0.2 degrees 2 & theta; With peaks.
Abstract:
Objective: amodafenib is a new type of non-amphetamine-type, this study was aimed to investigate the pharmacokinetics of a single oral dose of amodafenib tablets in Chinese healthy volunteers. Methods: A single-center, randomized, open-label, three-dose, three-cycle self-crossover trial was designed to select 12 healthy subjects who received a single dose of 100mg of oral amodafenib tablets, 200mg,400mg. Plasma concentrations were determined by LC-MS/MS, and pharmacokinetic parameters were analyzed by DAS 2.1.1 Software. Results: the main pharmacokinetic parameters of amodafenib tablets in different doses of 11.96±1.37 mg, 12.66±1.56 mg and MG were as follows: t1/2 was () h,() h and (13.13±1.05)h;Tmax (2.41±1.43),(2.50±1.28)h and (3.00±1.37)h;Cmax (3117±715.8)μg · L-1,(5952±1183)μg · L-1 and (11522±2821)μg · L-1;AUC0-t were (53549±12621)hr · μg · L-1,(108153±24191) hr · μg · L-1 and (226871±56430), respectively. hr · μg · L-1;AUC0-∞ were (55366±12427)hr · μg · L-1,(110526±25090)hr · μg · L-1 and (229359±56552), respectively. hr. Μg. L-1. Fever was the most common adverse reaction in clinical observation, with a total of 20 frequencies, and no serious adverse events were observed. Conclusion: the blood concentration of oral administration of amodafenib tablets reached the peak at 2.5 h-3h. There were no serious adverse reactions in the test dose range.
stowed
Key words:
armodafinil tablets, pharmacokinetics, security
meeting name:
The Third National Forum on pharmacokinetics of young scientists and Liu changxiao Talent Award conference
meeting place:
Nanjing, Jiangsu, China
Abstract:
modafinil can be used to treat narcolepsy and depression, but there are few reports of modafinil causing Mental Disorder at home and abroad. We report a case of Mental Disorder after high-dose combination of modafinil and amodafinil, which is expected to draw the attention of clinicians.
Key words:
Mental Disorder armodafinil modafinil
DOI:
10.3760/cma.j.cn113661-20190627-00217
year:
2020
from VIP
Author:
One quarter , Fan Xiaomei , Zhu Xiong
Abstract:
A HPLC method was established for the resolution of modafinil and the determination of the (S)-isomer of armodafinil. The α-acid glycoprotein (AGP) chiral stationary phase was used with the mobile phase of 0.05 mol/L ammonium acetate aqueous solution (containing 3% isopropanol, pH 6.8) at the detection wavelength of 225 nm, the (S)-isomer of armodafinil was completely separated with a detection limit of 0.05 μg/ml.
Key words:
DOI:
10.3969/j.issn.1001-8255.2010.03.017
cited:
year:
2010
Abstract:
as a new type of central stimulant drug, modafinil has shown good safety and efficacy in clinical studies, and has been widely used in clinical practice. As a levorotatory form of modafinil, armodafinil has a greater advantage than modafinil. In this paper, the crystal types, preparation methods and applications of modafinil and armodafinil are reviewed.
Key words:
modafinil; Amodafinil; crystal form
DOI:
CNKI:SUN:YAXU.0.2011-11-024
cited:
year:
2011